March 2014

Potential Parkinson’s Therapy secures $23M for testing from NIH

Monday, March 31, 2014

Results of a study funded by the Michael J. Fox Foundation (MJFF) for Parkinson’s Research have enabled researchers to secure a $23 million grant from the NIH, continuing a repurposed drug approved for hypertension to phase III testing for slowing Parkinson’s progression. The trial investigating the compound isradipine will be the most advanced, current study into a disease-modifying therapy for Parkinson’s disease (PD), an unmet need.

[Read More]

North Shore InnoVentures receives $1.65M from Massachusetts Life Sciences Center

Monday, March 31, 2014

North Shore InnoVentures (NSIV), a New England technology incubator and business accelerator, has received a capital grant of $1.65 million from the Massachusetts Life Sciences Center (MLSC). The grant will allow NSIV to expand its current laboratory facilities over the next three years and purchase advanced analytical instrumentation. This grant is part of a larger $5 million award to the Life Sciences Consortium of the North Shore (LSCNS), consisting of Endicott College, Gordon College, North Shore InnoVentures, North Shore Community College and Salem State University, that will fund major lab/facility and equipment upgrade projects at the member institutions and organizations.

[Read More]

Kite Pharma granted FDA Orphan Drug Designation for Anti-CD19

Monday, March 31, 2014

Kite Pharma, a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, has announced that the FDA Office of Orphan Products Development (OOPD) granted Orphan Drug Designation for the company’s lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL).

[Read More]

Janssen expands global cardiovascular research program with three new studies

Monday, March 31, 2014

Janssen R&D is adding three new clinical trials to its EXPLORER global cardiovascular research program for XARELTO (rivaroxaban), a broadly indicated oral Factor Xa inhibitor. The additional trials will evaluate rivaroxaban for the treatment or prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in pediatric and other patient populations, including those at risk for DVT or PE due to a concurrent medical illness. The new studies will include more than 11,000 patients in over 30 countries.

[Read More]

FDA approves Topamax for migraine prevention in adolescents

Monday, March 31, 2014

The FDA has approved Topamax (topiramate) for prevention (prophylaxis) of migraine headaches in adolescents ages 12 to 17. This is the first FDA approval of a drug for migraine prevention in this age group. The medication is taken on a dailybasis to reduce the frequency of migraine headaches.

[Read More]